- Home
- GOF vs IDYA Comparison
GOF vs IDYA Comparison
Compare GOF & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- IDYA
- Stock Information
- Founded
- GOF 2006
- IDYA 2015
- Country
- GOF United States
- IDYA United States
- Employees
- GOF N/A
- IDYA N/A
- Industry
- GOF Finance/Investors Services
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- GOF Finance
- IDYA Health Care
- Exchange
- GOF Nasdaq
- IDYA Nasdaq
- Market Cap
- GOF 2.3B
- IDYA 2.2B
- IPO Year
- GOF N/A
- IDYA 2019
- Fundamental
- Price
- GOF $15.25
- IDYA $26.23
- Analyst Decision
- GOF
- IDYA Strong Buy
- Analyst Count
- GOF 0
- IDYA 12
- Target Price
- GOF N/A
- IDYA $53.67
- AVG Volume (30 Days)
- GOF 789.2K
- IDYA 1.1M
- Earning Date
- GOF 01-01-0001
- IDYA 11-04-2024
- Dividend Yield
- GOF 15.42%
- IDYA N/A
- EPS Growth
- GOF N/A
- IDYA N/A
- EPS
- GOF N/A
- IDYA N/A
- Revenue
- GOF N/A
- IDYA $3,922,000.00
- Revenue This Year
- GOF N/A
- IDYA N/A
- Revenue Next Year
- GOF N/A
- IDYA $251.89
- P/E Ratio
- GOF N/A
- IDYA N/A
- Revenue Growth
- GOF N/A
- IDYA N/A
- 52 Week Low
- GOF $10.96
- IDYA $24.48
- 52 Week High
- GOF $16.76
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- GOF 36.77
- IDYA 37.58
- Support Level
- GOF $15.02
- IDYA $24.48
- Resistance Level
- GOF $15.81
- IDYA $27.15
- Average True Range (ATR)
- GOF 0.17
- IDYA 1.34
- MACD
- GOF -0.08
- IDYA -0.11
- Stochastic Oscillator
- GOF 23.71
- IDYA 7.90
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.